Role of statin in increasing the risk of diabetes mellitus
DOI:
https://doi.org/10.15419/bmrat.v4i12.391Abstract
Statin is known as one of the most commonly prescribed medicines in the United States (Bhattacharya et al., 2014). This drug is widely used with the aim to prevent risk of stroke and cardiovascular diseases as well as reduction of mortality from these diseases (Mohammadian et al., 2015; Ong et al., 2014). Several studies have recently paid attention to roles of Statins in increasing the risk of type 2 diabetes mellitus. Based on results of several clinical trials on prevention of cardiovascular diseases, Statin leads to an increased risk of type 2 diabetes mellitus (T2DM) (Crandall et al., 2017). This drug leads to an increase at fasting blood sugar, glycosylated hemoglobin (HbA1c) and blood sugar levels in recipients (Mohammadian et al., 2017; Ridker et al., 2012).
References
<li>Bhattacharya, R., Ajmera, M., Bhattacharjee, S., and Sambamoorthi, U. (2014). Use of antidepressants and statins and short-term risk of new-onset diabetes among high risk adults. Diabetes research and clinical practice 105, 251-260. <a href="https://doi.org/10.1016/j.diabres.2014.04.016">https://doi.org/10.1016/j.diabres.2014.04.016</a></li>
<li>Crandall, J.P., Mather, K., Rajpathak, S.N., Goldberg, R.B., Watson, K., Foo, S., Ratner, R., Barrett-Connor, E., and Temprosa, M. (2017). Statin use and risk of developing diabetes: results from the Diabetes Prevention Program. BMJ open diabetes research & care 5, e000438. <a href="https://doi.org/10.1136/bmjdrc-2017-000438">https://doi.org/10.1136/bmjdrc-2017-000438</a></li>
<li>Mohammadian, M., Hosseini, S., Sadeghi, M., Sarrafzadegan, N., Salehiniya, H., Roohafza, H., Khazaei, S., and Mohammadian-Hafshejani, A. (2015). Trends of 28 days case fatality rate after first acute myocardial infarction in Isfahan, Iran, from 2000 to 2009. ARYA atherosclerosis 11, 233-243.</li>
<li>Mohammadian, M., Salehiniya, H., Khazaei, S., and Mohammadian-Hafshejani, A. (2017). Intensification of Metformin treatment in diabetic patients with Insulin versus Sulfonylureas. Biomedical Research and Therapy 4, 1341-1343. <a href="https://doi.org/10.15419/bmrat.v4i06.177">https://doi.org/10.15419/bmrat.v4i06.177</a></li>
<li>Ong, K.L., Waters, D.D., Messig, M., DeMicco, D.A., Rye, K.A., and Barter, P.J. (2014). Effect of change in body weight on incident diabetes mellitus in patients with stable coronary artery disease treated with atorvastatin (from the treating to new targets study). The American journal of cardiology 113, 1593-1598. <a href="https://doi.org/10.1016/j.amjcard.2014.02.011">https://doi.org/10.1016/j.amjcard.2014.02.011</a></li>
<li>Ridker, P.M., Pradhan, A., MacFadyen, J.G., Libby, P., and Glynn, R.J. (2012). Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet (London, England) 380, 565-571. <a href="https://doi.org/10.1016/S0140-6736(12)61190-8">https://doi.org/10.1016/S0140-6736(12)61190-8</a></li>
<li>Sattar, N., Preiss, D., Murray, H.M., Welsh, P., Buckley, B.M., de Craen, A.J., Seshasai, S.R., McMurray, J.J., Freeman, D.J., Jukema, J.W., et al. (2010). Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet (London, England) 375, 735-742. <a href="https://doi.org/10.1016/S0140-6736(09)61965-6">https://doi.org/10.1016/S0140-6736(09)61965-6</a></li>
</ol>
Downloads
Published
Issue
Section
License
Copyright The Author(s) 2017. This article is published with open access by BioMedPress. This article is distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0) which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
